Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | GEN1029 |
Synonyms | |
Therapy Description |
GEN1029 consists of two non-competing antibodies targeting DR5 with enhanced hexamer formation capability, which may stimulate antibody-mediated tumor cell killing (Blood 2017 130(Suppl 1):1835, PMID: 32847982). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GEN1029 | HexaBody-DR5/DR5|GEN-1029|GEN 1029 | GEN1029 consists of two non-competing antibodies targeting DR5 with enhanced hexamer formation capability, which may stimulate antibody-mediated tumor cell killing (Blood 2017 130(Suppl 1):1835, PMID: 32847982). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03576131 | Phase Ib/II | GEN1029 | GEN1029 (HexaBody-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Terminated | USA | GBR | ESP | 0 |